Navigation Links
SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
Date:2/9/2009

Development activities are intended to support regulatory filings for S0812 and additional promising bitter blockers

SAN DIEGO, CA, February 9, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has initiated development activities for S0812 and additional new bitter blockers. The development phase includes scale-up production activities and safety studies to support regulatory filings for the bitter blockers in the U.S. and elsewhere.

"Senomyx has two collaborators for our Bitter Blocker Program. We are pleased to report that S0812 and additional bitter blockers met the criteria established by one of our collaborators for reducing the bitterness of their products," stated Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of the Company. "In conjunction with that collaborator, Senomyx has decided to initiate development activities intended to support regulatory filings for these promising bitter blockers."

"In addition to our two existing collaborations for the Bitter Blocker Program, we are using our proprietary technologies to create a novel 'toolbox' of bitter blockers that have the potential to be licensed to new partners to reduce the bitter taste of a wide variety of food, beverage, OTC healthcare, and pharmaceutical products," said Mark Zoller, Ph.D., Senomyx's Chief Scientific Officer and Executive Vice President of Discovery and Development.

"We believe that Senomyx's Bitter Blocker Program has the potential to generate meaningful long-term value for the Company," noted John Poyhonen, Senior Vice President, Chief Financial and Business Officer. "Reducing bitterness would be beneficial for the many manufacturers who would like to improve the taste characteristics of their products."

This is the fourth time that Senomyx has initiated development activities to support regulatory filings for new flavor ingredients discovered by the Company. Senomyx is currently conducting development activities for a new sucrose enhancer, S6973, which enables the reduction of up to 50% of the sugar present in product prototypes. In addition, both S2383, an enhancer of the high-intensity sweetener sucralose, and the Company's savory flavor ingredients have received Generally Recognized As Safe (GRAS) regulatory status, which allows commercialization in the U.S. and other countries.

"Senomyx has gained important experience managing several flavor ingredients through the development phase and successful regulatory reviews," Snyder noted. "We believe this expertise will be helpful as we conduct our development activities with the new bitter blockers."

Senomyx has an extensive intellectual property portfolio of proprietary taste receptor technologies, including patents related to bitter taste. Each individual has 25 different types of taste receptors that are associated with the perception of bitter taste (T2Rs). The Company has been granted patent claims that cover the use of amino acids and nucleic acid sequences that encode many T2R receptor subunits, as well as variants of these bitter receptors, for identifying new bitter taste modulators.

About Senomyx, Inc. (www.senomyx.com)

Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into product discovery, development, and commercialization collaborations with seven of the world's foremost food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. Nestle is currently marketing products that contain one of Senomyx's flavor ingredients. For more information, please visit www.senomyx.com.

Forward-Looking Statements

Statements included in this press release that are not a description of fact are forward-looking statements, including, but not limited to, statements regarding the commercial potential of S0812 and Senomyx's other bitter blockers, whether Senomyx's current and potential future collaborators will use bitter blockers in their products, the potential of our Bitter Blocker Program to generate significant long-term value for Senomyx, and whether we will enter into any new collaborations for bitter blockers in the future. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans, projections or future financial, scientific or business objectives will be achieved. Our actual results may differ materially from any projected future results set forth in this release as a result of the risks and uncertainties inherent in our business including, without limitation: difficulties or delays in developing, testing, obtaining regulatory approval, producing, and marketing our flavor ingredients and related technologies; whether we are able to complete the satisfactory development of our novel flavor ingredients, including S0812 or other bitter blockers, when expected or at all; whether our development activities for novel flavor ingredients will demonstrate commercially acceptable safety profiles for our compounds; the ability of our licensees to manufacture S0812 and other bitter blockers in commercial quantities at acceptable cost; whether we will be able to further extend or expand our existing collaborations or enter into additional collaborations in the future; our ability to collect royalties under our collaborations; the progress and timing of our scientific programs; changes in the laws or regulations of the United States and other countries that could adversely affect our and our collaborators' ability to develop and commercialize our products; whether any of our collaborations will result in the discovery and development of novel flavor ingredients, improve the nutritional profile of products incorporating them, or otherwise enhance our market position; our ability to protect our intellectual property and proprietary technology and to maintain and enforce our licensing arrangements with various third party licensors; our ability to define the scope and validity of patent protection for our products and technologies; competition from other companies and flavor manufacturers; and other risks detailed in our Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

    Contact:
    Gwen Rosenberg
    Senomyx, Inc.
    Vice President, Investor Relations & Corporate Communications
    (858) 646-8369
    gwen.rosenberg@senomyx.com


'/>"/>
SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009
2. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE
3. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
4. SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
5. SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
6. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
7. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE
9. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
10. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER
11. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... BRUNSWICK, N.J. , Feb. 3, 2016 /PRNewswire-USNewswire/ ... grants totaling more than $1 million for researchers ... are working on health-related research that demonstrates exciting ... this round of funding for the New Jersey ... for faculty members at these educational institutions— Princeton ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
Breaking Biology Technology:
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):